1. Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study 
Neil A. Hagen, MD, FRCPC, Patrick du Souich, MD, PhD, Bernard Lapointe, MD, May Ong-Lam, MD, FRCPC, Benoit Dubuc, MD, David Walde, MD, FRCPC, Robin Love, MD, CCFP, Anh Ho Ngoc, PhD 
Journal of Pain and Symptom Management 
Volume 35, Issue 4, Pages (April 2008)
DOI: /j.jpainsymman
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
Study design.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Average change in pain intensity after the subcutaneous administration of 30μg bid of TTX or placebo for four days in 36 and 37 patients, respectively.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Duration of analgesic response in the 14 patients who reported a ≥30% decrease in BPI#3, BPI#5, or in any of the three most bothersome pains.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
Distribution according to the randomization to TTX or placebo, the type of pain (neuropathic and nonneuropathic) and the response to TTX and placebo. The percentages listed in the figure reflect the percentage of responders in the indicated treatment group. For example, 18% of patients with neuropathic pain who were administered placebo, responded to the treatment according to the predetermined primary endpoint.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2008 U.S. Cancer Pain Relief Committee Terms and Conditions